AN-788

From Wikipedia, the free encyclopedia
AN-788
Clinical data
Other namesNSD-788
Drug classMonoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor
Identifiers
CAS Number

AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder.[1][2][3] It was also under development for anxiety disorders, but development for this indication was discontinued.[1] The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI).[1][2][3] As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder.[4]

See also[edit]

References[edit]

  1. ^ a b c "Initiator Pharma".
  2. ^ a b Shao L, Li W, Xie Q, Yin H (2014). "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opin Ther Pat. 24 (2): 131–54. doi:10.1517/13543776.2014.859676. PMID 24289044. S2CID 1825304.
  3. ^ a b Gerhard F. Ecker; Rasmus P. Clausen; Harald H. Sitte (16 December 2016). Transporters as Drug Targets. Wiley. pp. 36–. ISBN 978-3-527-67951-5.
  4. ^ "Initiator Pharma signs option agreement for Phase 2 ready drug candidate". News Powered by Cision. Retrieved 2022-02-08.